ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on

ADC Therapeutics to Host Third Quarter 2022

Financial Results Conference Call on November

Lausanne, Switzerland,

October 31, 2022 - ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on

Tuesday, November 8, 2022 at 8:30 a.m. ET to report financial results for the third quarter 2022 and provide business updates.

To access the conference

call, please register here. Registrants will receive

the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time.

A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics

website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

(NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted

antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm

for patients with hematologic malignancies and solid tumors.

CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse

large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents.

Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase

1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing

clinical and preclinical development.

is based in Lausanne (Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information,

please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA is a registered trademark

of ADC Therapeutics SA.

Tel.: +44 7879 627205

Tel.: +1 917 288 7023

Tel.: +1 914-552-4625